BioCentury
ARTICLE | Clinical News

Tekmira preclinical data

January 6, 2014 8:00 AM UTC

In non-human primates, once-daily 0.5 mg/kg TKM-Ebola for 7 days led to an 83% survival rate when treatment was initiated 24-48 hours after infection with the Zaire variant of Ebola virus and a 67% survival rate when treatment was initiated 72 hours after infection. No animals survived in the placebo arm or in the TKM-Ebola arm when treatment was initiated 96 hours after infection. Tekmira said it plans to start Phase I testing with a more "potent" formulation of the product this quarter, with data expected in 2H14. ...